Cargando…
Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective
BACKGROUND: A number of diabetic patients with diabetic neuropathy, in India, were treated with epalrestat, an aldose reductase inhibitor. In this study, more than 2000 patients with diabetic neuropathy, who were treated with epalrestat for 3-12 months, were analyzed to assess the efficacy and the a...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771994/ https://www.ncbi.nlm.nih.gov/pubmed/19893679 http://dx.doi.org/10.4103/0972-2327.44558 |